New drug combo tested against standard therapy in Hard-to-Treat myeloma

NCT ID NCT05028348

Ongoing Disease control Sponsor: European Myeloma Network B.V. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a combination of selinexor, pomalidomide, and dexamethasone works better than elotuzumab, pomalidomide, and dexamethasone for people with multiple myeloma that has come back or stopped responding to treatment. About 117 participants who have already tried 1 to 4 prior therapies will be randomly assigned to one of the two drug regimens. The main goal is to see which combination delays cancer progression longer and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selinexor (oral drug) combined with pomalidomide and dexamethasone
What this could lead to: If successful, this could offer a new treatment option for patients with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong: This is an early-stage comparison in a small group (117 people). The new combination may not prove better or could have more side effects than the standard regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens

Athens, Greece
CHRU Hôtel Dieu

Nantes, France
CHU Hôpital Saint Antoine

Paris, France
Clínica Universidad de Navarra (CUN)

Pamplona, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)

Santiago de Compostela, Spain
H. General Universitario Morales Meseguer

Murcia, Spain
H. Universitario Marqués de Valdecilla

Santander, Spain
H.U. La Fe

Valencia, Spain
Hospital Clinic I Provincial de Barcelona

Barcelona, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario de Salamanca

Salamanca, Spain
Hospital de Cabueñes

Gijón, Spain
Institut Catala D Oncolocia Hospitalet - Hospital Duran i Reynals

Barcelona, Spain
Institut Català D'Oncologia - Hospital Dr. Josep Trueta

Girona, Spain
Klinikum Chemnitz

Chemnitz, Germany
La Pitié

Paris, France
Marien Hospital Dusseldorf

Düsseldorf, Germany
University Medicine Greifswald, Medical Clinic and Polyclinic for Internal Medicine

Greifswald, Germany
Universitätsklinikum Hamburg - Eppendorf

Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.